Slide 1: The Power of a 12L ECG
The Power of a 12L ECG Always with the patient Third Quarter 2023 Financial Results Conference Call NASDAQ: BEAT November 14, 2023
Slide 2: Disclaimers
Third Quarter 2023 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position
Slide 3: Agenda
Third Quarter 2023 Financial Results Conference Call Agenda • Introduction and Company Overview Branislav Vajdic, PhD • Recent Updates Rob Eno • Financial Results Rick Brounstein • Closing Summary Branislav Vajdic, PhD • Q&A 30 years of experience in 28 years of experience with 30 years of experienc
Slide 4: Company Overview
Third Quarter 2023 Financial Results Conference Call Company Overview Branislav Vajdic, PhD 4
Slide 5: No Patient Friendly Heart Attack Solution in the Market
Third Quarter 2023 Financial Results Conference Call No Patient Friendly Heart Attack Solution in the Market 5
Slide 6: HeartBeam is a Cardiac Technology Company with a Credit Card-Size 3D-vector ECG Platform
Third Quarter 2023 Financial Results Conference Call HeartBeam is a Cardiac Technology Company that has Developed the First and Only Credit Card-Size 3D-vector Electrocardiogram (VECG) Platform for Patient Use at Home No Patient Friendly Heart Attack Solution in the Market • HeartBeam AIMIGo™ is the
Slide 7: HeartBeam US Market Opportunity
Third Quarter 2023 Financial Results Conference Call HeartBeam US Market Opportunity 6X Larger than Atrial Fibrillation Market • ~3 Million AFib Patients - $2 Billion Market • ~ 20 Million total Coronary Artery Disease (CAD) Patients - $12 Billion Market Unlocks Conditions Beyond Arrhythmias • AIMIG
Slide 8: HeartBeam IP Portfolio
Third Quarter 2023 Financial Results Conference Call HeartBeam IP Portfolio AIMIGo On Demand 12L Patch LIVMOR Watch Powerful, portable 12L ECG Extended wear patch that FDA-cleared prescription can produce 12L output wearable for continuous cardiac rhythm monitoring Integrated System HeartBeam Watch
Slide 9: Recent Updates
Third Quarter 2023 Financial Results Conference Call Recent Updates Rob Eno 9
Slide 10: Foundational Study Demonstrates Excellent Performance of VECG in Coronary Occlusion Detection
Third Quarter 2023 Financial Results Conference Call Foundational Study Demonstrates Excellent Performance of VECG in Coronary Occlusion Detection Unique study design tested HeartBeam technology vs. standard 12L ECG during coronary occlusions HEARTBEAM BASELINE ENHANCES HEARTBEAM WITH MATCHED 12L EC
Slide 11: Significantly Enhanced HeartBeam Team
Third Quarter 2023 Financial Results Conference Call Significantly Enhanced HeartBeam Team Added Dr. Michael R. Jaff to Board of Directors Rich Ferrari Branislav Vajdic, PhD Marga Ortigas–Wedekind Wim Elfrink Executive Chairman CEO & Founder Board Member Board Member George de Urioste Kenneth Nelson
Slide 12: Significantly Enhanced HeartBeam Team
Third Quarter 2023 Financial Results Conference Call Significantly Enhanced HeartBeam Team Three Key Members of Senior Management Branislav Vajdic, PhD Rob Eno Rick Brounstein Peter Fitzgerald, MD, PhD CEO & Founder President Chief Financial Officer Chief Medical Officer Ken Persen Richa Gujarati De
Slide 13: Significantly Enhanced HeartBeam Team
Third Quarter 2023 Financial Results Conference Call Significantly Enhanced HeartBeam Team Expanded Scientific Advisory Board Peter Fitzgerald, MD, PhD C. Michael Gibson, MD Charles L. Brown III, MD Tony Das, MD Chief Medical Officer SAB Chair SAB Member SAB Member Robert Harrington, MD Campbell Rog
Slide 14: Steady Progress Toward Key Product Milestones
Third Quarter 2023 Financial Results Conference Call Steady Progress Toward Key Product Milestones • Two FDA 510(k) submissions for HeartBeam AIMIGo • Version 1: AIMIGo Hardware (3 lead VECG collection device) • 510(k) submitted in May • Received and responded to questions from FDA • Version 2: soft
Slide 15: Financial Results
Third Quarter 2023 Financial Results Conference Call Financial Results Rick Brounstein 15
Slide 16: Q3 2023 Financial Highlights
Third Quarter 2023 Financial Results Conference Call Q3 2023 Financial Highlights $ in Thousands Quarters ended September 30, 2023 2022 Operating Expenses: General & Administrative $2,114 $2,048 Research & Development 1,623 1,562 Total Operating Expenses 3,737 3,610 Loss from Operations (3,737) (3,6
Slide 17: Closing Summary
Third Quarter 2023 Financial Results Conference Call Closing Summary Branislav Vajdic, PhD 17
Slide 18: Closing Summary
Third Quarter 2023 Financial Results Conference Call Closing Summary CONTINUED VALIDATION AND COMPANY MOMENTUM • Foundational study on detection of coronary artery occlusions published in JACC: Advances • Significantly enhanced the team: new Board of Directors members, expanded Scientific Advisory B
Slide 19: Q&A
Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050